Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 5:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 13,291 matching trials from the live ClinicalTrials.gov search.
Completed Phase 3 Interventional Accepts healthy volunteers

Efficacy of Ramelteon on Transient Insomnia in Healthy Adults

NCT00671398
Conditions
Transient Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 64 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
12
States / cities
Palm Springs, California • San Diego, California • Miami, Florida + 9 more
Conditions
Primary Hyperaldosteronism
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
San Francisco, California • Farmington, Connecticut • Springfield, Illinois + 11 more
Completed Phase 2 Interventional Results available

Safety and Efficacy of Secukinumab in Mild Psoriasis

NCT03131570
Conditions
Psoriasis
Interventions
Secukinumab, Placebo followed by Secukinumab
Drug
Lead sponsor
James G. Krueger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Lymphoma, Cancer, Thyroid Carcinoma
Interventions
XL184
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • New York, New York + 2 more
Completed Phase 2Phase 3 Interventional Results available

Age of Blood in Sickle Cell Transfusion

NCT03704922
Conditions
Sickle Cell Disease
Interventions
Transfusion
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina • Milwaukee, Wisconsin
Conditions
CNS
Interventions
E2006, Placebo comparator
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Culver City, California • Glendale, California
Conditions
Renal Failure
Interventions
LCP-Tacro tablets, Prograf
Drug
Lead sponsor
Asahi Kasei Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 10 more
Conditions
Type 2 Diabetes
Interventions
Specialized multidisciplinary diabetes team (SMDT) approach, Traditional model of care
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Major Depressive Disorder
Interventions
SEP-363856, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
929 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
53
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Conditions
Deep Vein Thrombosis
Interventions
Handgrip Exercises
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Cincinnati, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Smoking Cessation Treatment for Adult Women

NCT01422239
Conditions
Nicotine Dependence
Interventions
Tailored treatment, Standard Treatment
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 2 Interventional Results available

GB001 in Adult Subjects With Moderate to Severe Asthma

NCT03683576
Conditions
Asthma
Interventions
GB001, Placebo
Drug
Lead sponsor
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 41 more
Conditions
Acute Hypoxemic Respiratory Failure, Mechanical Ventilation, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Low-flow ECMO
Device
Lead sponsor
Institute for Extracorporeal Life Support
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Small Cell Lung Cancer Recurrent
Interventions
Debio 0123, Etoposide, Carboplatin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Completed Not applicable Interventional Accepts healthy volunteers

A Facebook Intervention for Young Sexual and Gender Minority Smokers

NCT03259360
Conditions
Tobacco Use, Smoking, Tobacco Dependence, Tobacco Use Disorder, Tobacco Use Cessation, Tobacco Smoking, Smoking Cessation, Smoking, Cigarette, Smoking, Tobacco
Interventions
POP:, TSP:
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 25 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of STAR-0215 in Healthy Adult Participants

NCT05477160
Conditions
Hereditary Angioedema
Interventions
STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV)
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Conditions
Autism Spectrum Disorder
Interventions
SDARI-YA, AYA
Behavioral · Other
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 30 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Colorectal Cancer
Interventions
adenoma vs no adenoma, colonoscopy vs no colonoscopy, survey and expert panel
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
75 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
San Diego, California • West Los Angeles, California
Conditions
Brain and Central Nervous System Tumors
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Mild Cognitive Impairment (MCI), Older Adults With Cognitive Decline, Older Adults
Interventions
Not listed
Lead sponsor
BioSensics
Industry
Eligibility
55 Years and older
Enrollment
100 participants
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Quadrivalent Influenza Vaccine Among Adults

NCT01218646
Conditions
Influenza
Interventions
Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative, Investigational Trivalent Inactivated Influenza Vaccine, No Preservative, Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
12
States / cities
Hoover, Alabama • South Miami, Florida • Springfield, Missouri + 9 more
Conditions
Knee Osteoarthritis
Interventions
Virtual Reality
Device
Lead sponsor
Tufts University
Other
Eligibility
60 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Conditions
Brain and Central Nervous System Tumors, Radiation Toxicity
Interventions
EGb761, donepezil hydrochloride, cognitive assessment
Dietary Supplement · Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
4
States / cities
Phoenix, Arizona • Rome, Georgia • Winston-Salem, North Carolina + 1 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

NCT02719327
Conditions
Alzheimer's Disease
Interventions
icosapent ethyl (IPE), gel cap placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin